vildagliptin + metformin + basal insulin

This is a combination therapy for type 2 diabetes mellitus consisting of three distinct agents: **vildagliptin**, a dipeptidyl-peptidase-4 (DPP-4) inhibitor; **metformin**, a biguanide antihyperglycemic agent; and **basal insulin** (such as insulin glargine, detemir, or degludec), which is a long-acting insulin analog. Vildagliptin increases endogenous incretin hormones (GLP-1 and GIP), which stimulate insulin secretion and suppress glucagon in a glucose-dependent manner. Metformin reduces hepatic glucose production, decreases intestinal absorption of glucose, and increases insulin sensitivity. Basal insulin provides prolonged, steady insulin coverage to control fasting blood glucose. The combination aims for robust glycemic control, especially in patients inadequately controlled by oral agents alone, and can reduce insulin requirements and improve glycemic variability without increasing hypoglycemia or weight gain risk[1][3][4].